Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response
© 2024. The Author(s)..
INTRODUCTION: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, is indicated for preventive treatment of migraine in adults. Real-world evidence assessing the effect of fremanezumab on migraine-related medication use, health care resource utilization (HCRU), and costs in patient populations with comorbidities, acute medication overuse (AMO), and/or unsatisfactory prior migraine preventive response (UPMPR) is needed.
METHODS: Data for this US, retrospective claims analysis were obtained from the Merative® MarketScan® Commercial and supplemental databases. Eligible adults with migraine initiated fremanezumab between 1 September 2018 and 30 June 2019 (date of earliest fremanezumab claim is the index date), had ≥ 12 months of continuous enrollment prior to initiation (preindex period) and ≥ 6 months of data following initiation (postindex period; variable follow-up after 6 months), and had certain preindex migraine comorbidities (depression, anxiety, and cardiovascular disease), potential AMO, or UPMPR. Changes in migraine-related concomitant acute and preventive medication use, HCRU, and costs were assessed pre- versus postindex.
RESULTS: In total, 3193 patients met the eligibility criteria. From pre- to postindex, mean (SD) per patient per month (PPPM) number of migraine-related acute medication and preventive medication claims (excluding fremanezumab), respectively, decreased from 0.97 (0.90) to 0.86 (0.87) (P < 0.001) and 0.94 (0.74) to 0.81 (0.75) (P < 0.001). Migraine-related outpatient and neurologist office visits, emergency department visits, and other outpatient services PPPM decreased pre- versus postindex (P < 0.001 for all), resulting in a reduction in mean (SD) total health care costs PPPM from US$541 (US$858) to US$490 (US$974) (P = 0.003). Patients showed high adherence and persistence rates, with mean (SD) proportion of days covered of 0.71 (0.29), medication possession ratio of 0.74 (0.31), and persistence duration of 160.3 (33.2) days 6 months postindex.
CONCLUSIONS: Patients with certain migraine comorbidities, potential AMO, and/or UPMPR in a real-world setting had reduced migraine-related medication use, HCRU, and costs following initiation of fremanezumab. Graphical abstract available for this article.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
Pain and therapy - (2024) vom: 12. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Buse, Dawn C [VerfasserIn] |
---|
Links: |
---|
Themen: |
Acute medication overuse |
---|
Anmerkungen: |
Date Revised 13.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1007/s40122-024-00583-9 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM36962369X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM36962369X | ||
003 | DE-627 | ||
005 | 20240313235254.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240313s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40122-024-00583-9 |2 doi | |
028 | 5 | 2 | |a pubmed24n1326.xml |
035 | |a (DE-627)NLM36962369X | ||
035 | |a (NLM)38472655 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Buse, Dawn C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 13.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024. The Author(s). | ||
520 | |a INTRODUCTION: Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related peptide, is indicated for preventive treatment of migraine in adults. Real-world evidence assessing the effect of fremanezumab on migraine-related medication use, health care resource utilization (HCRU), and costs in patient populations with comorbidities, acute medication overuse (AMO), and/or unsatisfactory prior migraine preventive response (UPMPR) is needed | ||
520 | |a METHODS: Data for this US, retrospective claims analysis were obtained from the Merative® MarketScan® Commercial and supplemental databases. Eligible adults with migraine initiated fremanezumab between 1 September 2018 and 30 June 2019 (date of earliest fremanezumab claim is the index date), had ≥ 12 months of continuous enrollment prior to initiation (preindex period) and ≥ 6 months of data following initiation (postindex period; variable follow-up after 6 months), and had certain preindex migraine comorbidities (depression, anxiety, and cardiovascular disease), potential AMO, or UPMPR. Changes in migraine-related concomitant acute and preventive medication use, HCRU, and costs were assessed pre- versus postindex | ||
520 | |a RESULTS: In total, 3193 patients met the eligibility criteria. From pre- to postindex, mean (SD) per patient per month (PPPM) number of migraine-related acute medication and preventive medication claims (excluding fremanezumab), respectively, decreased from 0.97 (0.90) to 0.86 (0.87) (P < 0.001) and 0.94 (0.74) to 0.81 (0.75) (P < 0.001). Migraine-related outpatient and neurologist office visits, emergency department visits, and other outpatient services PPPM decreased pre- versus postindex (P < 0.001 for all), resulting in a reduction in mean (SD) total health care costs PPPM from US$541 (US$858) to US$490 (US$974) (P = 0.003). Patients showed high adherence and persistence rates, with mean (SD) proportion of days covered of 0.71 (0.29), medication possession ratio of 0.74 (0.31), and persistence duration of 160.3 (33.2) days 6 months postindex | ||
520 | |a CONCLUSIONS: Patients with certain migraine comorbidities, potential AMO, and/or UPMPR in a real-world setting had reduced migraine-related medication use, HCRU, and costs following initiation of fremanezumab. Graphical abstract available for this article | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Acute medication overuse | |
650 | 4 | |a Adherence | |
650 | 4 | |a CGRP | |
650 | 4 | |a Costs | |
650 | 4 | |a Fremanezumab | |
650 | 4 | |a HCRU | |
650 | 4 | |a Migraine | |
650 | 4 | |a Real-world evidence | |
700 | 1 | |a Krasenbaum, Lynda J |e verfasserin |4 aut | |
700 | 1 | |a Seminerio, Michael J |e verfasserin |4 aut | |
700 | 1 | |a Packnett, Elizabeth R |e verfasserin |4 aut | |
700 | 1 | |a Carr, Karen |e verfasserin |4 aut | |
700 | 1 | |a Ortega, Mario |e verfasserin |4 aut | |
700 | 1 | |a Driessen, Maurice T |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pain and therapy |d 2012 |g (2024) vom: 12. März |w (DE-627)NLM240485173 |x 2193-8237 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:12 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40122-024-00583-9 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 12 |c 03 |